SCHEMBL2964542

SCHEMBL2964542

Cc1cc(Cl)nc2c1c(OC(=O)N1CCC(C)CC1)nn2C(=O)N1CCC(C)CC1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.39
ALDH1A1 P00352 3/20 0.39
MEN1 O00255 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
KMT2A Q03164 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HPGD P15428 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
HTT P42858 2/20 0.37
RAB9A P51151 1/20 0.37
HRH3 Q9Y5N1 2/20 0.34
TSHR P16473 2/20 0.34
TP53 P04637 1/20 0.34
POLB P06746 1/20 0.33
GRM5 P41594 1/20 0.32
LIPE Q05469 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16242498 0.88 HPGD (0.35) GAAALDH1A1MEN1CYP1A2CYP3A4
SCHEMBL1573748 0.84 SMN1; SMN2 (0.40) ALDH1A1KMT2AHPGDSMN1; SMN2HTT
SCHEMBL2962458 0.82 GAA (0.35) GAAALDH1A1MEN1CYP1A2CYP3A4
SCHEMBL1573996 0.78 SPR (0.35) HRH3
SCHEMBL1573736 0.77 SPR (0.35) HPGDLIPE
SCHEMBL1574115 0.77 GAA (0.41) GAAALDH1A1MEN1CYP1A2CYP3A4
SCHEMBL1573805 0.74 HRH3 (0.35) HRH3
SCHEMBL1573795 0.73 GAA (0.45) GAAALDH1A1MEN1CYP1A2CYP3A4
SCHEMBL2957829 0.72 GAA (0.41) GAAALDH1A1MEN1CYP1A2CYP3A4
SCHEMBL4844841 0.72 HPGD (0.32) HPGDSMN1; SMN2HTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1937648-B1 DIACYL INDAZOL DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS SANOFI SA (FR) 2014-11-26 EP disclosed
US-8357698-B2 Diacyl indazole derivatives as lipase and phospholipase inhibitors SANOFI (FR) 2013-01-22 US disclosed
US-20100286133-A1 Diacyl indazole derivatives as lipase and phospholipase inhibitors SANOFI-AVENTIS (FR) 2010-11-11 US disclosed
US-7772268-B2 inhibitors of hormone-sensitive lipase and/or endothelial lipase; for treatment of diabetes mellitus, dyslipidemia and atherosclerotic disorders SANOFI-AVENTIS (FR) 2010-08-10 US disclosed
US-20080287448-A1 Diacyl indazole derivatives as lipase and phospholipase inhibitors SANOFI-AVENTIS (FR) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287448-A1 Diacyl indazole derivatives as lipase and phospholipase inhibitors PNLIP, DAGLA, MGLL GAA 231/4885ALDH1A1 959/4885MEN1 3008/4885
US-20100286133-A1 Diacyl indazole derivatives as lipase and phospholipase inhibitors PNLIP, DAGLA, MGLL GAA 231/4885ALDH1A1 959/4885MEN1 3008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.